JAC Advance Access published online on January 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh089
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Institute for Medical Microbiology and Epidemiology of Infectious
Diseases, University of Leipzig, Liebigstr. 24,
D-04103 Leipzig, Germany
* Corresponding author. E-mail: schaur{at}medizin.uni-leipzig.de.
Received 30 June 2003
; revised 14 October 2003
; accepted 27 November 2003
Objectives: To study the effect of
moxifloxacin versus imipenem/cilastatin (hereafter referred to as imipenem)
treatment on the mortality of mice infected intravenously with different
strains of Bacteroides fragilis and Escherichia
coli. Methods: Groups of 20 mice each were infected
intravenously with different strains of B. fragilis [moxifloxacin
and imipenem susceptible or resistant, and enterotoxin (ET) positive
or negative] and E. coli (moxifloxacin
and imipenem susceptible). Twenty-four hours post-infection, intravenous
therapy with either moxifloxacin (2.0 mg twice a day) or imipenem
(2.4 mg three times a day) was started and continued for
3 days. Control groups were left untreated. Survival rates
were recorded at day 7 post-infection. At that time, surviving mice
were killed and numbers of bacteria in the liver and kidneys were
determined. Results: If compared with untreated animals,
mice treated with either moxifloxacin or imipenem showed significantly
improved survival (P < 0.001). There was
no significant difference (P = 0.97) in
the survival rates comparing the two treatment regimens irrespective
of the ET positivity or the susceptibility to moxifloxacin or imipenem
of the infective B. fragilis strain. However, there
was a tendency that B. fragilis was recovered more
often from the liver and kidneys of mice infected with ET positive
strains. Conclusions: The data show that moxifloxacin
was as efficacious as imipenem in reducing the mortality rate of
mice suffering from a severe systemic aerobic/anaerobic infection.
Keywords: aerobic/anaerobic infections, mouse model of
infection, treatment of mixed infections
Effect of moxifloxacin versus imipenem/cilastatin
treatment on the mortality of mice infected intravenously with different
strains of Bacteroides fragilis and Escherichia
coli
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Noel, K. E. Bowker, and A. P. MacGowan Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4234 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schaumann, E. J. Goldstein, J. Forberg, and A. C Rodloff Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures J. Med. Microbiol., August 1, 2005; 54(8): 749 - 753. [Abstract] [Full Text] [PDF]
|
|